PD-L1 expression and immune profiling cannot predict osimertinib efficacy in lung cancer with EGFR T790 M mutation: A translational study.
Yang CY, Liao WY, Ho CC, Chen KY, Tsai TH, Hsu CL, Su KY, Chang YL, Wu CT, Hsu CC, Liu YN, Peng GR, Kangartaputra AA, Yu SH, Liao BC, Hsu WH, Lee JH, Lin CC, Shih JY, Chih-Hsin Yang J, Yu CJ.
Yang CY, et al. Among authors: yu cj.
J Formos Med Assoc. 2024 Dec 17:S0929-6646(24)00579-5. doi: 10.1016/j.jfma.2024.12.020. Online ahead of print.
J Formos Med Assoc. 2024.
PMID: 39694766